PUBLICATIONS

Featured Research

Leveraging a deep bench of expertise and foundational experience in DNA medicine development, we’re driving research that has the potential to transform treatment paradigms and improve patients’ lives.

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Nature Medicine (October 2025)
READ MORE →
DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications (February 2025)
READ MORE →
Vaccines for HPV-associated diseases

Molecular Aspects of Medicine (December 2023)
READ MORE →
Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope (May 2023)
READ MORE →

Showing 1-10 of 53 results.

TITLE DISEASE TARGET PROGRAM

Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers

Frontiers in Immunology (November 2025)

DISEASE TARGET MERS

PROGRAM INO-4700

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Nature Medicine (October 2025)

DISEASE TARGET COVID-19

PROGRAM N/A

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

Frontiers in Immunology (October 2025)

DISEASE TARGET Lassa

PROGRAM INO-4500

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Nature Communications (February 2025)

DISEASE TARGET RRP

PROGRAM INO-3107

Vaccines for HPV-associated diseases

Molecular Aspects of Medicine (December 2023)

DISEASE TARGET N/A

PROGRAM N/A

Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation

Molecular Therapy - Nucleic Acids (December 2023)

DISEASE TARGET N/A

PROGRAM N/A

Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models

Human Vaccines & Immunotherapeutics (November 2023)

DISEASE TARGET COVID-19

PROGRAM N/A

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Laryngoscope (May 2023)

DISEASE TARGET RRP

PROGRAM INO-3107

Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection

Cancer Prevention Research (March 2023)

DISEASE TARGET Hepatitis C

PROGRAM INO-8000 + INO-9012

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape

Molecular Therapy - Oncolytics (March 2023)

DISEASE TARGET GBM

PROGRAM N/A

Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo

Frontiers in Immunology (February 2023)

DISEASE TARGET Melanoma

PROGRAM N/A

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

The Journal of Infectious Diseases (January 2022)

DISEASE TARGET COVID-19

PROGRAM INO-4800

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

Open Forum Infectious Diseases (December 2021)

DISEASE TARGET COVID-19

PROGRAM INO-4800

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

npj Vaccines (October 2021)

DISEASE TARGET COVID-19

PROGRAM INO-4800

Immunogenicity of a DNA vaccine candidate for COVID-19

Nature Communications (May 2020)

DISEASE TARGET COVID-19

PROGRAM INO-4800

CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens

Molecular Therapy (March 2020)

DISEASE TARGET N/A

PROGRAM N/A

IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses

Journal of Hepatology (February 2020)

DISEASE TARGET Hepatitis C

PROGRAM GLS-6150

Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis

Vaccines (January 2020)

DISEASE TARGET RRP

PROGRAM INO-3107

Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge

Human Vaccines & Immunotherapeutics (December 2019)

DISEASE TARGET Zika

PROGRAM INO-A002

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

The Lancet Infectious Diseases (July 2019)

DISEASE TARGET MERS

PROGRAM INO-4700

Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses

Vaccine (June 2019)

DISEASE TARGET N/A

PROGRAM CELLECTRA

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity

JCI Insight (April 2019)

DISEASE TARGET N/A

PROGRAM N/A

In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus

Molecular Therapy (April 2019)

DISEASE TARGET Zika

PROGRAM INO-A002

Intradermal SynCon^® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

The Journal of Infectious Diseases (March 2019)

DISEASE TARGET Ebola

PROGRAM INO-4201

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Clinical Cancer Research (January 2019)

DISEASE TARGET Head & Neck Cancer

PROGRAM INO-3112, MEDI0457

Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus

Microbes and Infection (December 2018)

DISEASE TARGET Zika

PROGRAM INO-4600

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

Cell Reports (November 2018)

DISEASE TARGET Ebola

PROGRAM N/A

Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo

Cancer Research (November 2018)

DISEASE TARGET N/A

PROGRAM N/A

Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines

The Journal of Infectious Diseases (October 2018)

DISEASE TARGET Ebola

PROGRAM INO-4201

Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization

The Journal of Infectious Diseases (July 2018)

DISEASE TARGET Zika

PROGRAM INO-4600

Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine

Vaccine (May 2018)

DISEASE TARGET Influenza

PROGRAM N/A

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy

Clinical Cancer Research (January 2018)

DISEASE TARGET Cervical Dysplasia

PROGRAM VGX-3100

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT

Molecular Therapy (November 2017)

DISEASE TARGET N/A

PROGRAM INO-5401

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report

The New England Journal of Medicine (October 2017)

DISEASE TARGET Zika

PROGRAM INO-4600

An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model

Nature Communications (September 2017)

DISEASE TARGET Pseudomonas

PROGRAM N/A

Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody

Cancer Immunology, Immunotherapy (August 2017)

DISEASE TARGET Prostate Cancer

PROGRAM N/A

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

npj Vaccines (July 2017)

DISEASE TARGET Influenza

PROGRAM N/A

DNA vaccination protects mice against Zika virus-induced damage to the testes

Nature Communications (June 2017)

DISEASE TARGET Zika

PROGRAM INO-4600

A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity

Molecular Therapy (February 2017)

DISEASE TARGET N/A

PROGRAM INO-5401

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

npj Vaccines (November 2016)

DISEASE TARGET Zika

PROGRAM INO-4600

Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis

BMJ (July 2016)

DISEASE TARGET Cervical Dysplasia

PROGRAM VGX-3100

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

The Journal of Infectious Diseases (March 2016)

DISEASE TARGET Chikungunya

PROGRAM N/A

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

Molecular Therapy Oncolytics (January 2016)

DISEASE TARGET Cervical Dysplasia

PROGRAM VGX-3100

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

The Lancet (September 2015)

DISEASE TARGET Cervical Dysplasia

PROGRAM VGX-3100

A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

Science Translational Medicine (August 2015)

DISEASE TARGET MERS

PROGRAM INO-4700

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

Scientific Reports (July 2015)

DISEASE TARGET Dengue

PROGRAM N/A

Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals

Molecular Therapy (March 2015)

DISEASE TARGET HIV

PROGRAM PENNVAX-GP

HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo

PLoS ONE (December 2013)

DISEASE TARGET HIV

PROGRAM PENNVAX-GP

Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity

Cancer Immunology Research (September 2013)

DISEASE TARGET N/A

PROGRAM INO-5401

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

Science Translational Medicine (October 2012)

DISEASE TARGET Cervical Dysplasia

PROGRAM VGX-3100

A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle

Vaccine (September 2011)

DISEASE TARGET N/A

PROGRAM CELLECTRA

Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine

Vaccine (September 2011)

DISEASE TARGET HIV

PROGRAM PENNVAX-GP

Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses

Human Vaccines (January 2011)

DISEASE TARGET N/A

PROGRAM INO-5401

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Vaccines for HPV-associated diseases

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Filter Results: (select all that apply)

Safety, tolerability, and immunogenicity of a DNA-based vaccine (INO-4700) against Middle East respiratory syndrome coronavirus: phase 2a study in healthy volunteers

Safety and pharmacokinetics of SARS-CoV-2 DNA-encoded monoclonal antibodies in healthy adults: a phase 1 trial

Safety, tolerability, and immunogenicity of INO-4500, a synthetic DNA-based vaccine against Lassa virus, in a phase 1b clinical trial in healthy Ghanaian adults

DNA immunotherapy for recurrent respiratory papillomatosis (RRP): phase 1/2 study assessing efficacy, safety, and immunogenicity of INO-3107

Vaccines for HPV-associated diseases

Intradermal DNA vaccine delivery using vacuum-controlled, needle-free electroporation

Delineation of DNA and mRNA COVID-19 vaccine-induced immune responses in preclinical animal models

Interim Results of a Phase 1/2 Open-Label Study of INO-3107 for HPV-6 and/or HPV-11-Associated Recurrent Respiratory Papillomatosis

Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection

Multivalent in vivo delivery of DNA-encoded bispecific T cell engagers effectively controls heterogeneous GBM tumors and mitigates immune escape

Engineered antibody cytokine chimera synergizes with DNA-launched nanoparticle vaccines to potentiate melanoma suppression in vivo

SARS-CoV-2 DNA Vaccine INO-4800 Induces Durable Immune Responses Capable of Being Boosted in a Phase 1 Open-Label Trial

571. Safety and Immunogenicity of INO-4800, a COVID-19 DNA Vaccine as a Primary Series and Booster

INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants

Immunogenicity of a DNA vaccine candidate for COVID-19

CD8+ T Cells Impact Rising PSA in Biochemically Relapsed Cancer Patients Using Immunotherapy Targeting Tumor-Associated Antigens

IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T-cell frequency and increases virus-specific T-cell responses

Immune Therapy Targeting E6/E7 Oncogenes of Human Papillomavirus Type 6 (HPV-6) Reduces or Eliminates the Need for Surgical Intervention in the Treatment of HPV-6 Associated Recurrent Respiratory Papillomatosis

Synthetic nucleic acid antibody prophylaxis confers rapid and durable protective immunity against Zika virus challenge

Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial

Integration of needle-free jet injection with advanced electroporation delivery enhances the magnitude, kinetics, and persistence of engineered DNA vaccine induced immune responses

DNA-encoded bispecific T cell engagers and antibodies present long-term antitumor activity

In Vivo Delivery of a DNA-Encoded Monoclonal Antibody Protects Non-human Primates against Zika Virus

Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers

Immunotherapy Targeting HPV16/18 Generates Potent Immune Responses in HPV-Associated Head and Neck Cancer

Rapid response to an emerging infectious disease – Lessons learned from development of a synthetic DNA vaccine targeting Zika virus

In Vivo Delivery of Synthetic Human DNA-Encoded Monoclonal Antibodies Protect against Ebolavirus Infection in a Mouse Model

Synthetic DNA-Encoded Monoclonal Antibody Delivery of Anti–CTLA-4 Antibodies Induces Tumor Shrinkage In Vivo

Protective Efficacy and Long-Term Immunogenicity in Cynomolgus Macaques by Ebola Virus Glycoprotein Synthetic DNA Vaccines

Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization

Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine

Clinical and Immunologic Biomarkers for Histologic Regression of High-Grade Cervical Dysplasia and Clearance of HPV16 and HPV18 after Immunotherapy

Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT

Safety and Immunogenicity of an Anti–Zika Virus DNA Vaccine — Preliminary Report

An engineered bispecific DNA-encoded IgG antibody protects against Pseudomonas aeruginosa in a pneumonia challenge model

Novel prostate cancer immunotherapy with a DNA-encoded anti-prostate-specific membrane antigen monoclonal antibody

DMAb inoculation of synthetic cross reactive antibodies protects against lethal influenza A and B infections

DNA vaccination protects mice against Zika virus-induced damage to the testes

A Novel DNA Vaccine Platform Enhances Neo-antigen-like T Cell Responses against WT1 to Break Tolerance and Induce Anti-tumor Immunity

In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine

Adverse obstetric outcomes after local treatment for cervical preinvasive and early invasive disease according to cone depth: systematic review and meta-analysis

Rapid and Long-Term Immunity Elicited by DNA-Encoded Antibody Prophylaxis and DNA Vaccination Against Chikungunya Virus

Augmentation of cellular and humoral immune responses to HPV16 and HPV18 E6 and E7 antigens by VGX-3100

Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial

A synthetic consensus anti–spike protein DNA vaccine induces protective immunity against Middle East respiratory syndrome coronavirus in nonhuman primates

Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy

Synthetic Consensus HIV-1 DNA Induces Potent Cellular Immune Responses and Synthesis of Granzyme B, Perforin in HIV Infected Individuals

HIV-1 Env DNA Vaccine plus Protein Boost Delivered by EP Expands B- and T-Cell Responses and Neutralizing Phenotype In Vivo

Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity

Immunotherapy Against HPV16/18 Generates Potent TH1 and Cytotoxic Cellular Immune Responses

A novel prototype device for electroporation-enhanced DNA vaccine delivery simultaneously to both skin and muscle

Immunogenicity of a novel engineered HIV-1 clade C synthetic consensus-based envelope DNA vaccine

Co-delivery of PSA and PSMA DNA vaccines with electroporation induces potent immune responses

Intradermal SynCon^® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers